ערך בספרים למניה: inmunebio.com (INMB)

INmune Bio, Inc. (INMB) minimizes biotech risks by developing treatments for cancer and dementia through immune activation. Disciplined management effectively allocates capital toward platform validation. The BVPS trend helps assess the value of net assets, where the indicator is fixed at 0.76. The company's advantage is the innovative XPro, which treats neuroinflammation in Alzheimer's disease while preserving the overall immune response.

INmune Bio, Inc. (INMB) is creating long-term capitalization potential through its proprietary platforms for the development of innovative Alzheimer's disease and oncology therapies. This chart of historical book value visualizes the difference between total assets and liabilities per share, allowing investors to assess the real value of net assets and determine the extent to which the asset is overvalued relative to its tangible fundamentals.